CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
Lara Chavaz, Léna Royston, Stavroula Masouridi‐Levrat, Anne‐Claire Mamez, Federica Giannotti, Sarah Morin, Christian van Delden, Yves Chalandon, Dionysios Neofytos
Abstract
In this single-center study of 61 allogeneic hematopoietic cell transplant (HCT) recipients receiving letermovir primary cytomegalovirus (CMV) prophylaxis for the first 100 days, we report 23% incidence of clinically significant CMV infection during the first 100 days after letermovir discontinuation, predominately in haploidentical HCT recipients, without any associations with CMV-DNAemia under letermovir.
Topics & Concepts
MedicineDiscontinuationHematopoietic cellInternal medicineHematopoietic stem cell transplantationOncologyHaematopoiesisImmunologyTransplantationIntensive care medicineStem cellGeneticsBiologyCytomegalovirus and herpesvirus researchHerpesvirus Infections and TreatmentsParvovirus B19 Infection Studies